Format

Send to

Choose Destination
Clin Cancer Res. 2019 Aug 15;25(16):4881-4887. doi: 10.1158/1078-0432.CCR-18-1894. Epub 2019 Mar 25.

Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer.

Author information

1
Department of Pulmonology, Helios Klinikum Schleswig, Schleswig, Germany. dheigener@aol.com.
2
Christian-Albrechts-University, Kiel, Germany.
3
Airway Research Center North in the German Center for Lung Research (DZL), Grosshansdorf, Germany.
4
Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, Scotland.
5
Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
6
Institute of Oncology NN Petrov-Saint Petersburg, Pesochny, Russia.
7
St. Petersburg City Cancer Center, St. Petersburg, Russia.
8
LungenClinic Grosshansdorf, Grosshansdorf, Germany.
9
University of Lübeck, Lübeck,Germany.

Abstract

Metastatic non-small-cell lung cancer is still a devastating disease; however, treatment options have diversified dramatically in the past two decades. From unselected platinum-based chemotherapy for all patients, several different treatment groups have evolved, that is, those with "druggable" targets, those with a promising immune signature, and those without any predicting factors outlined in this article. Challenge includes the intersections between these groups and the optimal treatment path. These issues will be addressed in this review.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center